Journal
BRITISH JOURNAL OF HAEMATOLOGY
Volume 199, Issue 2, Pages 239-244Publisher
WILEY
DOI: 10.1111/bjh.18357
Keywords
chronic lymphocytic leukaemia; ibrutinib; treatment; venetoclax
Categories
Funding
- Henry J. Predolin Foundation
Ask authors/readers for more resources
Patients with disease refractory to commonly used novel agents, such as ibrutinib, may benefit from combined treatment with ibrutinib and venetoclax, as shown in this retrospective study.
Patients with chronic lymphocytic leukaemia (CLL) disease progression on ibrutinib or after sequential ibrutinib and venetoclax-based treatments (double-refractory) have poor outcomes. In this retrospective study, we analysed outcomes with combined ibrutinib and venetoclax treatment in these groups of patients. The median treatment-free and overall survival for 22 patients with prior progression on ibrutinib (venetoclax-naive) were 23.7 and 47.1 months respectively. In 11 patients with double-refractory CLL, the median treatment-free and overall survival were 11.2 and 27.0 months respectively. The combination of ibrutinib and venetoclax may help bridge the current gap in options for patients with disease refractory to the most commonly used novel agents.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available